Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
HeXun Biosciences Co's Net-Net Working Capital for the quarter that ended in Jun. 2026 was NT$15.22.
The industry rank for HeXun Biosciences Co's Net-Net Working Capital or its related term are showing as below:
ROCO:6986's Price-to-Net-Net-Working-Capital is ranked better than 74.43% of 837
companies
in the Biotechnology industry
Industry Median: 5.36
vs ROCO:6986: 2.75
HeXun Biosciences Co (ROCO:6986) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
HeXun Biosciences Co Net-Net Working Capital Related Terms
HeXun Biosciences Co Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for HeXun Biosciences Co's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co Net-Net Working Capital Chart
ROCO:6986 vs VRTX, REGN, MRNA: Net-Net Working Capital Comparison
For the Biotechnology subindustry, HeXun Biosciences Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of NT$15.22 mean?
HeXun Biosciences Co (ROCO:6986) has a Net-Net Working Capital of NT$15.22 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on HeXun Biosciences Co According to the industry distribution chart, HeXun Biosciences Co ranks #214 out of 837 companies in the Biotechnology industry, placing it in the top 25.6%.
Is HeXun Biosciences Co's Net-Net Working Capital too high?
HeXun Biosciences Co's current Net-Net Working Capital is NT$15.22. Based on the distribution chart, HeXun Biosciences Co ranks #214 out of 837 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HeXun Biosciences Co has a GF Score™ of 42/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #214 out of 837 companies for Net-Net Working Capital. This puts HeXun Biosciences Co in the upper half of its industry. The industry median Net-Net Working Capital is 5.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.36, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on HeXun Biosciences Co For the Biotechnology industry, the median Net-Net Working Capital is 5.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeXun Biosciences Co's current Net-Net Working Capital is NT$15.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, HeXun Biosciences Co (ROCO:6986) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$109.72, compared to a current price of NT$41.80 — trading 61.9% below its estimated fair value. The current Net-Net Working Capital is NT$15.22. HeXun Biosciences Co's overall GF Score™ is 42/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Net-Net Working Capital is NT$15.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HeXun Biosciences Co (ROCO:6986) Overvalued in 2026?
Based on GuruFocus' analysis, HeXun Biosciences Co stock appears to be undervalued.
The current stock price of NT$41.80 is trading 61.9% below its estimated GF Value™ of NT$109.72.
GuruFocus considers HeXun Biosciences Co to be Significantly Undervalued.
Key valuation signals for ROCO:6986:
Net-Net Working Capital: NT$15.22
GF Value™: NT$109.72 vs. price of NT$41.80 (61.9% below fair value)
No single metric tells the full story. See the ROCO:6986 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
42GF Score
Get the complete analysis for ROCO:6986
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
